Search clinical trials for: Eylea®

Total 13905 results

Bayer

Completed

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice (MAIA)

Retinal Disease

Mexico
Allergan

Completed

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

Macular Edema | Retinal Vein Occlusion

United States
Neurotech Pharmaceuticals

Terminated

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Macular Degeneration

United States, Israel
Novartis Pharmaceuticals

Completed

Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (SALT)

Neovascular Age-related Macular Degeneration

Germany, Austria, Belgium, Denmark, Switzerland, France, Netherlands, Portugal, Sweden, Norway
Retinal Consultants of Arizona
Ophthotech Corporation

Completed

An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Ophthotech Corporation

Terminated

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Age-Related Macular Degeneration

United States
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Sam Chun Dang Pharm. Co. Ltd.

Completed

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States, Australia, Bulgaria, Czechia, Hungary, India, Israel, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Slovakia, Spain
Amgen
Parexel

Completed

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Spain, United States, Czechia, Serbia, Israel, Canada, Germany, Japan, Hungary, Poland, Korea, Republic of, Estonia, Hong Kong, Italy, Latvia, Lithuania, Mexico, Slovakia
Amgen

Completed

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

Chorioretinal Vascular Disease

United States
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Age-Related Macular Degeneration

France, Israel, Italy, United States, Spain, Portugal, Germany, Austria, Canada, Czechia, Estonia, Latvia, Poland, Slovakia, Australia, Hungary, Croatia, Argentina, Finland, Brazil, Colombia, Norway
Southeast Retina Center, Georgia

Completed

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab (ROTATED)

Diabetic Macular Edema

United States
Celltrion

Completed

Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema

Diabetic Macular Edema (DME)

Slovakia
Alteogen, Inc.

Completed

Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD

Neovascular Age-related Macular Degeneration

Korea, Republic of
Medical University of Graz

Active, not recruiting

Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration (FAN)

Neovascular Age-related Macular Degeneration

Austria
Santen Inc.

Completed

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration (VAPOR1)

Age-Related Macular Degeneration

United States
Hadassah Medical Organization
Bayer

Unknown

Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.

Neovascular Age-related Macular Degeneration

Israel
Regeneron Pharmaceuticals

Completed

Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

Chorioretinal Vascular Disease

United States
Alcon Research

Completed

Efficacy and Safety Study of ESBA1008 Versus EYLEA®

Exudative Age-Related Macular Degeneration
Mylan Pharmaceuticals Inc
Momenta Pharmaceuticals, Inc.

Completed

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) (DME)

Diabetic Macular Edema

Japan, United States, Czechia, Germany, Hungary, India, Latvia, Poland, Russian Federation
Alvotech Swiss AG

Active, not recruiting

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (ALVOEYE)

Neovascular (Wet) AMD

Slovakia, Czechia, Georgia, Japan, Latvia
Bioeq GmbH

Completed

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration (MAGELLAN-AMD)

Neovascular Age-related Macular Degeneration

Bulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia
McMaster University

Active, not recruiting

Mean Visual Acuity Changes Following Five Injections of Aflibercept

Diabetic Macular Edema

Canada
Regeneron Pharmaceuticals
Bayer

Completed

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration (CANDELA)

Neovascular (Wet) Age-Related Macular Degeneration

United States, Puerto Rico
Regeneron Pharmaceuticals

Terminated

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA)

Neovascular Age-Related Macular Degeneration

United States, Japan
Benha University

Recruiting

BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

Macula Lutea Degeneration

United Arab Emirates
Seoul National University Hospital

Completed

Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity

Age-Related Macular Degeneration

Korea, Republic of
Indonesia University
Bayer

Completed

Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection

Diabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular Edema

Indonesia
Regeneron Pharmaceuticals
Bayer

Active, not recruiting

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (PHOTON)

Type 2 Diabetes Mellitus | Diabetic Macular Edema | Type 1 Diabetes Mellitus

United States, Puerto Rico, Japan, United Kingdom, Canada, Czechia, Germany, Hungary
Cinnagen

Completed

Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration

Iran, Islamic Republic of
Regeneron Pharmaceuticals

Completed

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

Diabetic Macular Edema | Neovascular Age-Related Macular Degeneration

United States
St. Erik Eye Hospital

Unknown

Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

Branch Retinal Vein Occlusion With Macular Edema

Sweden
AbbVie

Recruiting

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

CNV | AMD | nAMD | Wet Age-related Macular Degeneration | wAMD | WetAMD

United States, Puerto Rico, Canada
Regeneron Pharmaceuticals
Bayer

Completed

Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema (VISTA DME)

Diabetic Macular Edema

United States
Regeneron Pharmaceuticals
Bayer

Completed

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO) (VIBRANT)

Branch Retinal Vein Occlusion

United States, Japan, Canada
Unity Biotechnology, Inc.

Completed

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

Neovascular Age-related Macular Degeneration

United States
Regeneron Pharmaceuticals

Completed

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (BUTTERFLEYE)

Retinopathy of Prematurity

United States, Bulgaria, Hungary, Russian Federation, Thailand, Turkey, Colombia, Czechia, Korea, Republic of, Romania, Slovakia, Taiwan, Vietnam
Regeneron Pharmaceuticals

Completed

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA)

Nonproliferative Diabetic Retinopathy

United States, Germany, Hungary, Japan, Puerto Rico, United Kingdom
Mylan Pharmaceuticals Inc
Momenta Pharmaceuticals, Inc.

Completed

Extension Study of MYL-1701P-3001 for Safety and Efficacy

Diabetic Macular Edema

India
Regeneron Pharmaceuticals

Not yet recruiting

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Diabetic Macular Edema (DME) | Neovascular Age-Related Macular Degeneration (nAMD)
Regeneron Pharmaceuticals

Completed

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)

Neovascular Age-Related Macular Degeneration

United States
Regeneron Pharmaceuticals
Bayer

Completed

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)

Diabetic Macular Edema

United States
Tennessee Retina
Regeneron Pharmaceuticals

Unknown

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept (TRISTAR)

Neovascular Age-related Macular Degeneration

United States
Regeneron Pharmaceuticals
Bayer

Completed

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration

United States, Canada
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Diabetic Retinopathy
Iconic Therapeutics, Inc.

Terminated

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (DECO)

Choroidal Neovascularization | Wet Macular Degeneration

United States
Alcon Research

Completed

Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 (HARRIER)

Choroidal Neovascularization | Neovascular Age-Related Macular Degeneration

3

Subscribe